Privileged structure based ligands for melanocortin receptors—Substituted benzylic piperazine derivatives
摘要:
Replacement of the aryl piperazine moiety in compound I with a variety of substituted benzylic piperazines (6) yields compounds that afford melanocortin receptor 4 (MCR4) activity. Analogs with ortho substitution on the aromatic ring afforded the highest affinity. Resolution of the stereocenter of the benzylic piperazine based privileged structure revealed that the R-enantiomer was more active. (c) 2005 Elsevier Ltd. All rights reserved.
Privileged structure based ligands for melanocortin receptors—Substituted benzylic piperazine derivatives
摘要:
Replacement of the aryl piperazine moiety in compound I with a variety of substituted benzylic piperazines (6) yields compounds that afford melanocortin receptor 4 (MCR4) activity. Analogs with ortho substitution on the aromatic ring afforded the highest affinity. Resolution of the stereocenter of the benzylic piperazine based privileged structure revealed that the R-enantiomer was more active. (c) 2005 Elsevier Ltd. All rights reserved.
The present invention relates to melanocortin receptor agonist of the formula I useful in the treatment of obesity, diabetes, and male and/or female sexual dysfunction
1
本发明涉及公式I的黑色素细胞激素受体激动剂,用于治疗肥胖症、糖尿病以及男性和/或女性性功能障碍。
MELANOCORTIN RECEPTOR AGONISTS
申请人:ELI LILLY AND COMPANY
公开号:EP1358163A1
公开(公告)日:2003-11-05
US7160886B2
申请人:——
公开号:US7160886B2
公开(公告)日:2007-01-09
US7169777B2
申请人:——
公开号:US7169777B2
公开(公告)日:2007-01-30
[EN] MELANOCORTIN RECEPTOR AGONISTS<br/>[FR] AGONISTES DE RECEPTEURS DE MELANOCORTINE
申请人:LILLY CO ELI
公开号:WO2002059095A1
公开(公告)日:2002-08-01
The present invention relates to melanocortin receptor agonist of the formula I useful in the treatment of obesity, diabetes, and male and/or female sexual dysfunction.